Skip to main content
. 2021 May 7;19(5):e3001209. doi: 10.1371/journal.pbio.3001209

Fig 2. Characterization of the selected NAbs PR1077, PR953, and PR961.

Fig 2

(A) ELISA binding curve of SARS-CoV-2 S1 protein. A commercially available antibody (8A5, Novoprotein, Shanghai) was applied as a PC. Normal human IgG1 was used as a negative control. All the data of this figure can be found in the S3 Data file. ELISA binding curves of SARS S1 (B) and MERS S1 (C) proteins. Internally generated antibodies were used as PCs. All the data of these figures can be found in the S4 Data and S5 Data files. (D) ELISA-based RBA of PR1077, PR953, and PR961 against RBD binding to hACE2. All the data of this figure can be found in the S6 Data file. (E) PR1077, PR953, and PR961 could effectively neutralize SARS-CoV-2 pseudovirus in vitro. SARS-CoV-2 pseudovirus was incubated with serially diluted antibodies. The mixture was added to HEK293-hACE2 cells for 48 hours. The neutralization potency of each antibody was evaluated in a luciferase assay system. All the data of this figure can be found in the S7 Data file. (F) PR1077, PR953, and PR961 showed strong neutralizing potency against live SARS-CoV-2 virus in vitro. The mixture of live SARS-CoV-2 virus and serially diluted PR1077 were added to Vero E6 cells. After 1 hour, cells were washed and further incubated for 48 hours before detection of infected cells by an immunofluorescence assay. All the data of this figure can be found in the S8 Data file. ELISA, enzyme-linked immunosorbent assay; NAb, neutralizing antibody; PC, positive control; RBA, receptor blocking assay; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.